Recently, a cDNA from the hepatitis C virus (HCV) RNA genome has been isolated In the USA froa a chronically infected chimpanzee. In order to Isolate HCV cDNA derived from human material, RNA was extracted from plasma of a Japanese blood donor implicated in post-transfusion non-A, non-B hepatitis and HCV cDNA was synthesized and amplified by the PCR method using HCV-speciflc oligonucleotlde priners. The cDNA fragment, 583 nucleotides long, showed 79.8\ honology at the nucleotide level and 92.2\ homology at the amino acid level compared with the prototype HCV cDNA. These results provides further evidence to show that HCV is closely associated with the developnent of post transfusion non-A, non-B hepatitis.
INTRODUCTION
A cDNA of the hepatitis C virus (HCV) genome has recently been cloned from an infected chimpanzee which developed non-A, non-B hepatitis following inoculation with a contaminated human factor VIII concentrate (1) . HCV Is a nember of the positive-strand RNA viruses, related to either the flaviviridae or togaviridae (1) . Seroepidemlological studies based on the detection of antibody against a recombinant HCV antigen (C100-3) suggest that HCV is associated with most posttransfusion non-A, non-B hepatitis (PTNANBH) cases around the world, including Japan (2) . Further examination has shown that antI-C100-3 antibody detected by this assay seems closely associated with the infectivlty of HCV, because most blood tranfusions resulting in the development of PTNANBH have been shown to contain at least one unit of antibody-positive blood (3).
To examine whether antibody-positive blood does indeed contain HCV virions, we have attempted to directly isolate HCV cDNA derived from plasma of an lnplicated blood donor and have investigated the degree of homology with the original chimpanzee isolate.
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MATERIALS AND METHODS
cDHA synthesis and PCR anpllflcatlon HCV virlons in plasma of an implicated donor were pelleted by ultracentrifugation according to the procedure described previously (4) and RNA was extracted by the guanidlnium/cesium chloride nethod (5) . The RNA was further purified by phenol/chloroforu extraction in the presence of urea (6) . RNA obtained from lml of plasma was used for cDNA synthesis with both 10 units of reverse transcriptase (BioRad) and 1 ug of an antlsense primer 526A, 5'-GACATGCATGTCATGATGTA-3', by the method described previously (7).
The cDNA was then amplified by polymerase chain reaction (PCR) using the standard nethod (8) 
Cloning and sequencing
The cDNA fragment anplified by the PCR method was visualized by ethidium bromide staining. A DNA band of the expected size was exised from the gel, purified and cloned by blunt-end ligatlon into the Smal site of pUC119 (9) .
Three independent clones were Isolated and their nucleotide sequences were determined by dideoxy chain termination method.
RESULTS
Isolation of HCV cDNA derived from an inpltcated donor
A Japanese male patient developed typical PTNANBH after receiving six units (1 unit Is 200 ml) of blood transfusion. Samples of the blood donations were retrospectively assayed for the C100-3 antibody and one donor blood sample was found to contain HCV antibody. The plasaa of the implicated donor was used as a starting material for cDNA cloning. cDNA was synthesized using the RNA extracted fron the plasna as template with the synthetic ollgonucleotide primer 526A, which is specific to the putative non-structural region 3 (NS3) of the prototype HCV (Choo et al., manuscript in preparation). The cDNA was then aapllfled by PCR method after adding the priner 464S, the 3' end of which is 583 nucleotides (nt) upstreaa fron the Sequence analysis of the HCV cDNA
The nucleotide lengths of these three cDNA clones were Identical (623 bp), but there were five nucleotide differences (see Discussion). Therefore, we constructed a consensus sequence (named Jl) of the three clones and coapared the Jl sequence with the sequences of the chimpanzee derived HCV cDNA (PT for prototype) (Fig. 1) . The nucleotide homology between Jl and PT is 79.8* Underline, different nucleotides.
(465/583 nt), while the amlno acid honology is higher (92.2*. 179/194 anino acids). When aslno acid honology was analysed in such a way that functionally sinilar anino acids are regarded as homologous, the homology reaches 98.5% (191/194 amino acids). Therefore, the sequence of the Japanese HCV cDNA significantly different fron the original isolate at the nucleotide level but it is highly houologous at the anino acid level.
We observed five nucleotide differences anong the three independent cDNA clones ( Table 1 ). These differences nay be explained as artifacts of the PCR amplification (8) or they may reflect viral heterogeneity: out of these five different nucleotides, three fall on the third letters of the codons and do not change the anino acid. Both of the remaining two different nucleotides fall on the first letter of the codons and change a«ino acids from Thr to Ala, and fron Pro to Ala, all of which are snail, neutral amlno acid residues. These results strongly suggest that the observed nucleotide differences reflect genuine viral genome heterogeneity.
DISCUSSION
We have shown that the HCV genoae can be detected In plasaa from an Implicated blood donor identified by the HCV C100-3 antibody assay. This result provides further evidence that the antl-C100-3 antibody Is associated with HCV infectivity, and confirms the rationale of the usefulness of this antibody test in blood screening.
The HCV cDNA isolated here showed only 79.8* homology with the prototype HCV cDNA sequence. As a result, the two cDNAs do not hybridize stably under stringent washing conditions and it was necessary to try several different primers to isolate the new cDNA. In spite of the low nucleotide homology, the amino acid sequences are highly conserved. Surprisingly, out of 118 different nucleotides, 103 (87.3%) are silent mutations. Moreover, out of 15 amino acid differences, 11 are changes between related anino acids, such as lie to Val, etc. (Fig. 1) . The result is consistent with our previous seroepidemiological studies which have shown that the reconbinant C100-3 antibody assay derived fron the prototype HCV cDNA can detect most cases of PTNANBH in USA, Japan and Italy.
Although the C100-3 antibody detection systen has been developed, a routine assay for viral antigen has not yet been developed. Therefore, the detection of the HCV genome by cDNA synthesis and PCR amplification probably represents a valuable direct assay for the HCV virions in near future.
